title: Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction.
abstract: OBJECTIVE
  To evaluate the pharmacokinetic interaction and bioequivalence of a combination formulation of the angiotensin-converting enzyme inhibitor fosinopril and the diuretic hydrochlorothiazide (HCTZ).
  
  
  METHODS
  In an open-label, balanced, randomized incomplete block, three-way crossover fashion, healthy men received single doses of three of four regimens in one of two independent studies. Regimens for study A (36 subjects): (1) fosinopril 10-mg tablet, (2) HCTZ 12.5-mg tablet, (3) a combination tablet of fosinopril 10 mg plus HCTZ 12.5 mg, or (4) coadministered tablets of fosinopril 10 mg and HCTZ 12.5 mg. Study B (40 subjects) received: (1) fosinopril 20-mg tablet, (2) HCTZ 12.5-mg tablet, (3) a combination tablet of fosinopril 20 mg plus HCTZ 12.5 mg, or (4) coadministered tablets of fosinopril 20 mg and HCTZ 12.5 mg.
  
  
  RESULTS
  There was no evidence of any significant effect of HCTZ on the pharmacokinetics of fosinoprilat, based on maximum concentration value, AUC, or cumulative urinary recovery over 24 hours. Fosinoprilat had no clinically important effect on the pharmacokinetics of HCTZ only slightly decreasing its AUC by 14% in study A. Coadministration was well tolerated; no new adverse events were reported with the combination tablet.
  
  
  CONCLUSIONS
  Fosinopril and HCTZ in a combination tablet display pharmacokinetic profiles similar to those achieved when either drug is administered alone or when coadministered in separate tablets. When used with HCTZ, the favorable pharmacokinetic feature of fosinopril, dual and compensatory pathways of renal and hepatic elimination, is preserved.
authors.affiliation: Bristol-Myers Squibb Clinical Research Unit, Hamilton, NJ 08690, USA.
authors.forename: H D
authors.initials: HD
authors.lastname: Uderman
authors.forename: D R
authors.initials: DR
authors.lastname: Much
authors.forename: J
authors.initials: J
authors.lastname: Brennan
authors.forename: C L
authors.initials: CL
authors.lastname: Delaney
authors.forename: E A
authors.initials: EA
authors.lastname: Morgenthien
authors.forename: J
authors.initials: J
authors.lastname: Weaver
authors.forename: B C
authors.initials: BC
authors.lastname: Stouffer
authors.forename: S Y
authors.initials: SY
authors.lastname: Chang
authors.forename: D
authors.initials: D
authors.lastname: VanHarken
authors.forename: W
authors.initials: W
authors.lastname: Liao
mesh_terms: D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004232:Diuretics; D004338:Drug Combinations; D004347:Drug Interactions; D017328:Fosinopril / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D008297:Male; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D017328:Fosinopril